Brokerages predict that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will announce $0.34 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sucampo Pharmaceuticals’ earnings. The highest EPS estimate is $0.36 and the lowest is $0.32. Sucampo Pharmaceuticals reported earnings of $0.68 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The firm is scheduled to report its next earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.12 per share for the current fiscal year, with EPS estimates ranging from $1.09 to $1.14. For the next fiscal year, analysts anticipate that the firm will post earnings of $1.19 per share, with EPS estimates ranging from $1.05 to $1.36. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same quarter last year, the business posted $0.30 earnings per share. The firm’s revenue was up 5.9% compared to the same quarter last year.

A number of equities research analysts recently issued reports on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, October 17th. UBS Group lowered their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, October 12th. Maxim Group set a $23.00 price objective on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 7th. B. Riley increased their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Finally, BidaskClub upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $21.58.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the sale, the insider now owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Krensavage Asset Management LLC grew its stake in shares of Sucampo Pharmaceuticals by 0.6% during the second quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock valued at $29,607,000 after buying an additional 16,570 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Sucampo Pharmaceuticals during the third quarter valued at about $21,989,000. Vanguard Group Inc. grew its stake in shares of Sucampo Pharmaceuticals by 13.0% during the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares during the last quarter. Finally, Royce & Associates LP grew its stake in shares of Sucampo Pharmaceuticals by 9.7% during the third quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock valued at $13,826,000 after buying an additional 103,808 shares during the last quarter. 64.55% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Sucampo Pharmaceuticals (SCMP) traded down $0.35 during mid-day trading on Monday, hitting $18.05. The company had a trading volume of 1,562,916 shares, compared to its average volume of 4,180,000. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $18.75. The stock has a market capitalization of $841.80, a P/E ratio of -5.39, a PEG ratio of 5.07 and a beta of 1.45.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/15/sucampo-pharmaceuticals-inc-scmp-expected-to-announce-earnings-of-0-34-per-share.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.